Drugs / Sodium Sulfide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00879645 | Aug 2009 → Mar 2010 | impaired renal function disease | Mallinckrodt | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01007461 | Dec 2009 | ST-elevation myocardial infarction | Mallinckrodt | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Sulfide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01007461 ↗ |
| Known as | Na2S | “IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion.” NCT01007461 ↗ |
| Route | Intravenous | “for intravenous (IV) injection or continuous infusion.” NCT01007461 ↗ |